Reduced Selenium-Binding Protein 1 in Breast Cancer Correlates with Poor Survival and Resistance to the Anti-Proliferative Effects of Selenium

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Sheng ^a   Li, Feng ^a   Younes, Mamoun ^b   Liu, Hao ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN SELENBP1; SELENIUM; SELENIUM BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CORRELATION ANALYSIS; DOWN REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; ORGANOSELENIUM COMPOUNDS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELENIUM; SELENIUM-BINDING PROTEINS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877990763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063702     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E,et al. (2011) Global cancer statistics. CA Cancer J Clin.
2. Shamberger RJ, Frost DV, (1969) Possible protective effect of selenium against human cancer. Can Med Assoc J 100: 682.
3. Yang M, Sytkowski AJ, (1998) Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58: 3150-3153.
4. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276: 1957-1963.
5. Surai PF (2006) Selenium in Nutrition and Health. Nottingham University Press, Nottingham.
6. Zeng H, Combs GF Jr, (2008) Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19: 1-7.
7. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, et al. (2005) Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65: 3487-3492.
8. Papp LV, Lu J, Holmgren A, Khanna KK, (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9: 775-806.
9. Behne D, Kyriakopoulos A, (2001) Mammalian selenium-containing proteins. Annu Rev Nutr 21: 453-473.
10. Chang PW, Tsui SK, Liew C, Lee CC, Waye MM, et al. (1997) Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J Cell Biochem 64: 217-224.
11. Lanfear J, Fleming J, Walker M, Harrison P, (1993) Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis. Carcinogenesis 14: 335-340.
12. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, et al. (2004) Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202: 321-329.
13. Li LS, Kim H, Rhee H, Kim SH, Shin DH, et al. (2004) Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 4: 3394-3400.
14. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, et al. (2004) Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4: 3276-3287.
15. Huang KC, Park DC, Ng SK, Lee JY, Ni X, et al. (2006) Selenium binding protein 1 in ovarian cancer. Int J Cancer 118: 2433-2440.
16. Kim H, Kang HJ, You KT, Kim SH, Lee KY, et al. (2006) Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6: 3466-3476.
17. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, et al. (2006) Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45: 613-626.
18. Bansal MP, Mukhopadhyay T, Scott J, Cook RG, Mukhopadhyay R, et al. (1990) DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 11: 2071-2073.
19. Giometti CS, Liang X, Tollaksen SL, Wall DB, Lubman DM, et al. (2000) Mouse liver selenium-binding protein decreased in abundance by peroxisome proliferators. Electrophoresis 21: 2162-2169.
20. Li T, Yang W, Li M, Byun DS, Tong C, et al. (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52: 1289-1299.
21. Zhang J, Dong WG, Lin J, (2011) Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol 28: 481-487.
22. Yager JD, Davidson NE, (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
23. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL, (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894.
24. Sutherland RL, Prall OW, Watts CK, Musgrove EA, (1998) Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3: 63-72.
25. Kyprianou N, English HF, Davidson NE, Isaacs JT, (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166.
26. Wang TT, Phang JM, (1995) Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489.
27. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, et al. (2006) Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 13: 233-250.
28. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, et al. (2004) Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 95: 496-502.
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
30. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206.
31. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, et al. (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7: 286-296.
32. Raucci R, Colonna G, Guerriero E, Capone F, Accardo M, et al. (2011) Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta 1814: 513-522.
33. Zhang P, Zhang C, Wang X, Liu F, Sung CJ, et al. (2010) The expression of selenium-binding protein 1 is decreased in uterine leiomyoma. Diagn Pathol 5: 80.
34. Pohl NM, Tong C, Fang W, Bi X, Li T, et al. (2009) Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One 4: e7774.
35. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, et al. (2002) Proteomics of human breast ductal carcinoma in situ. Cancer Res 62: 6740-6749.
36. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984.
37. Lai TC, Chou HC, Chen YW, Lee TR, Chan HT, et al. (2010) Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res 9: 1302-1322.
38. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, et al. (2009) Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118: 33-43.